/Company/Board of Directors
D. Troy Moore (Chairman of the Board):

Troy Moore is currently Chief Scientific Officer and a co-founder of Kailos Genetics, Inc.  Troy brings over 17 years of experience in the development of biotechnology companies. He was a co-founder of Open Biosystems in 2002, where he served as the Chief Technology Officer until the company was acquired by Thermo Fisher Scientific. As the Chief Technology Officer of Open Biosystems, Troy was responsible for the development of new products, technology licensing and collaborative research.  Troy was previously the Director of Genomic Resources at Invitrogen following their acquisition of Research Genetics in 2000. At Research Genetics, Troy was the Director of Genomic Libraries, where his responsibilities included technology licensing, new product development and whole genome resource distribution (domestic and international). Prior to joining Research Genetics, Troy participated in academic research focused on natural product development.

James R. Hudson, Jr. (Director):
Mr. Hudson serves as co-chairman of the board of directors of the HudsonAlpha Institute for Biotechnology, a non-profit research institute founded in Huntsville with a mission to use biotechnology to improve human health, stimulate economic development and inspire Alabama’s youth to seek careers in science.  He also serves as vice president of biosecurity-focused Concero Scientific and as president of CityScapes LLC, a company focused on downtown revitalization projects in Huntsville, Alabama.  In 1987, he founded Research Genetics in Huntsville, Ala. He served as chief executive until 2000 when the company merged with Invitrogen (IVGN).  Prior to the merger, Research Genetics had become the world’s leader in genetic linkage products and an integral partner in the Human Genome Project.  Mr. Hudson earned a master’s degree in physics from the University of Alabama and a master’s degree in biology from the University of Alabama in Huntsville.

Jason Chung (Director):
Jason has 18 years of investment experience in both private and public companies, which experience includes extensive trading in equity, fixed income, and derivative securities. For the last 12 years, Jason has worked as an advisor, board member, and executive of many start-up companies and in such capacity has helped with business development, capital raising, strategic partnerships and licensing agreements. Jason currently serves on the board of three privately-held companies. Jason served as a Vice President of both Prudential Securities and SG Cowen. Jason was a Managing Director of Pretium Capital Group, Inc., which is a Huntsville based investment banking firm. Jason also served as Portfolio Manager for Caxton Associates LLC, a New York based multi-strategy hedge fund.

Gwen D.  Fewell, PhD (Director):
 
Gwen is Chief Commercial Officer at SynVivo Inc, a biotechnology company whose proprietary microfluidic platform has applications in drug development and Precision Medicine. Gwen co-founded transOMIC technologies and led corporate strategy and commercial operations and now serves on the Board of Directors.
 
With over 15 years experience in startup biotechnology and life science research market Gwen is a domain expert in life science technologies and market dynamics and has driven commercial strategy at both startup and large companies. Previously she led global product marketing of the RNAi and Gene Expression portfolio at Thermo Scientific Genomics and startup Open Biosystems. Gwen earned an M.S in Neurophysiology from University of Mumbai and a PhD in Neuroscience at Florida State University. She performed postdoctoral studies at Children’s Hospital, Cincinnati exploring the genetic role of homeobox genes in brain development and studied the genetics of pediatric medulloblastoma in the Department of NeuroOncology at MD Anderson Cancer Center in Houston, TX.